We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 25, 2022

Outcomes in Patients With Breast Cancer or Prostate Cancer Receiving Antiresorptive Therapy for Bone Metastases

Journal of Bone Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Bone Oncology
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study
J Bone Oncol 2022 Apr 01;33(2022)100420, A Jakob, MO Zahn, A Nusch, T Werner, R Schnell, M Frank, N Hamm, KU Däßler, C Losem, M Welslau, P Hoevel, K Potthoff

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading